These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21874106)

  • 1. A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy.
    Lee CE; Leslie WD; Czaykowski P; Gingerich J; Geirnaert M; Lau YK
    Curr Oncol; 2011 Aug; 18(4):e163-72. PubMed ID: 21874106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy.
    Lee CE; Leslie WD; Lau YK
    BMC Cancer; 2012 Mar; 12():103. PubMed ID: 22436542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of bone loss in men with prostate cancer.
    Higano CS
    J Urol; 2003 Dec; 170(6 Pt 2):S59-63; discussion S64. PubMed ID: 14610412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
    Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
    Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.
    Mohamad NV; Soelaiman IN; Chin KY
    Endocr Metab Immune Disord Drug Targets; 2017 Nov; 17(4):276-284. PubMed ID: 28925899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone health management in men undergoing ADT: examining enablers and barriers to care.
    Damji AN; Bies K; Alibhai SM; Jones JM
    Osteoporos Int; 2015 Mar; 26(3):951-9. PubMed ID: 25526712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
    Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
    BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review.
    Kim TJ; Koo KC
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32532121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer.
    Lomax AJ; Parente P; Gilfillan C; Livingston PM; Davis ID; Pezaro C
    Intern Med J; 2016 Feb; 46(2):141-8. PubMed ID: 25732203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of care provided to prostate cancer (PC) patients for prevention and treatment of osteoporosis induced by androgen deprivation therapy (ADT).
    Chahin R; Gulamhusein H; Breunis H; Alibhai SM
    Support Care Cancer; 2016 Nov; 24(11):4713-20. PubMed ID: 27370648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fracture risk in androgen deprivation therapy: a Canadian population based analysis.
    Lau YK; Lee E; Prior HJ; Lix LM; Metge CJ; Leslie WD
    Can J Urol; 2009 Dec; 16(6):4908-14. PubMed ID: 20003666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
    Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer.
    Gunner C; Gulamhusein A; Rosario DJ
    J Clin Urol; 2016 Dec; 9(2 Suppl):24-29. PubMed ID: 28344813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review.
    Edmunds K; Tuffaha H; Scuffham P; Galvão DA; Newton RU
    Support Care Cancer; 2020 Dec; 28(12):5661-5671. PubMed ID: 32699997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
    Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
    Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
    Schulman C; Irani J; Aapro M
    BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.